A statistic about weight-loss injections has been spreading fast on social media this month: that women who started GLP-1 medications were dramatically more likely to end up in paid work. The post that kicked it off drew over half a million views in a few days — and, as usual with viral numbers, the real study behind it is both more interesting and more careful than the headline version. Here is what the research actually found, what it does not show, and what it means for people in Ireland weighing up treatment.
Quick answer (September 2026)
A large US economics working paper — not yet peer-reviewed — reports that women who were not in paid work when they started a GLP-1 medication were about 27 percentage points more likely to be employed around 18 months later than a comparison group, and about 13 percentage points more likely overall.
It is an association seen in health-insurance and employment data, not proof that the medication causes employment. In Ireland, clinician-led GLP-1 treatment starts from €229 in total for the first month — a €49 service fee to Slimbr plus medication from €180 paid to the independent partner pharmacy.
Where the number came from
The figure comes from a 2026 working paper by economist Rebecca Diamond, published by the US National Bureau of Economic Research (NBER) and titled GLP-1–Induced Weight Loss and the Female Obesity Penalty. Working papers are how economists share findings early, before the slow machinery of peer review; they are respected, widely read — and explicitly preliminary.
The study followed large numbers of US women who began GLP-1 medications such as semaglutide, using insurance and employment records, and compared what happened to them against a carefully constructed comparison group. Among women who were not employed when they started treatment, employment rose by about 13 percentage points on average — and by roughly 27 percentage points among those who stayed on the medication for six months or longer, measured over about a year and a half.
The paper found other life changes too: women on GLP-1s were also more likely to marry over the same period. And the employment effect was concentrated among women — the "female obesity penalty" of the title refers to research suggesting weight carries a harsher labour-market penalty for women than for men.
Why the viral version isn't quite right
The post that went viral rounded the finding to "20–25 percentage points over 2 to 3 years". The paper's actual figures are different in both directions: smaller overall (about 13 points), but larger — roughly 27 points — among longer-duration users, and measured over about 18 months, not three years. Neither version is dishonest; both are the kind of compression that happens when research meets a character limit. But if you are going to make a decision based on a number, it is worth having the real one.
What the study does NOT show
This matters more than the headline, so it gets its own section:
- It is not proof of cause. The design is observational — the researchers compare groups and control for what they can measure, but they cannot run a randomised trial of careers. Something else about the women who started and stayed on treatment could partly explain the difference.
- It is not peer-reviewed yet. Working papers get revised; some get walked back. Treat it as emerging research, not settled fact.
- It is US data. Labour markets, hiring practices and healthcare access differ enormously between the United States and Ireland. The direction of the finding may travel; the size may not.
- It is not a promise about you. No clinician — and certainly no clinic — should ever present employment or relationship outcomes as a reason to take a medication. The medical case for treatment rests on health, not on a pay cheque.
Why researchers took the idea seriously at all
Behind the new paper sits an older, better-established literature on weight stigma in hiring: studies over many years have found that candidates with higher body weights can face measurable disadvantage in recruitment and wages, with the effect repeatedly documented as stronger for women. If that penalty is real, then an effective medical treatment for obesity might reasonably be expected to show up somewhere in employment data — which is exactly the pattern this paper reports.
The new finding did not appear out of nowhere; it landed on top of two decades of prior research pointing the same direction.
See how the claim works →The Irish context: what treatment actually involves here
Nothing about the study changes the basics of accessing treatment in Ireland. GLP-1 medications are prescription-only medicines, prescribed after a genuine medical review — an online assessment, a clinician's decision, and regulated pharmacy dispensing. It is the same whether your motivation is health conditions like pre-diabetes, joint pain, or simply the daily toll the whole subject takes on you.
On cost, the verified figures: the first month starts at €229 in total — a €49 service fee to Slimbr plus medication from €180 paid to the independent partner pharmacy. After that, monthly plans run from €279 in total depending on dose, and the 6-month plan works out at about €253 per month. Delivery is charged by the pharmacy. We have a full breakdown in our cost guide, and the complete Mounjaro Ireland guide covers how the treatment works.
One thing worth carrying over from the research, though, has nothing to do with employment: whatever brings someone to treatment, protecting muscle while losing weight is the part that determines how the story ends — strength, energy, and keeping the weight off long after the pay-cheque question has settled itself.
The bottom line
Take the viral post as a pointer, not a promise. The honest version: early US research suggests that effective medical weight-loss treatment may quietly remove one of the disadvantages women with obesity face at work — a finding consistent with what stigma research has shown for years, and one that will need peer review and replication before anyone can rely on it. The medical case for treatment has never rested on it, and never will.
If you are considering treatment, the starting point is the same as it always was: a proper medical assessment, a clinician who can say no, and a plan built around your health.
Frequently asked questions
Does taking a GLP-1 help you get a job?
One US working paper reports an association between GLP-1 use and higher employment among women who were not previously in paid work. It is early-stage, observational research — not proof of cause, not peer-reviewed, and not a reason anyone should start a medication.
Was the viral "20–25%" statistic accurate?
Not exactly. The paper behind it reports about a 13 percentage-point rise in employment overall, rising to roughly 27 percentage points among women who used the medication for six months or more, over around 18 months of follow-up — not 20–25 points over 2–3 years.
How much does GLP-1 treatment cost in Ireland?
From €229 in total for the first month — a €49 service fee to Slimbr plus medication from €180 paid to the independent partner pharmacy. Monthly plans after that start at €279 in total depending on dose, and the 6-month plan averages about €253 per month. Delivery is charged by the pharmacy.
